Bharat Parenterals Ltd — Important, 18-05-2026: Company Update

The company released its investor presentation for Q4 and the full financial year ended March 31, 2026, signaling the completion of a key investment phase and an expected commercial inflection in FY27. Consolidated revenue reached ₹345.4 Cr for FY26, with EBITDA at ₹15.8 Cr. Innoxel Lifesciences secured ₹72.4 Cr licensing revenue, achieving USFDA EIR and EU-GMP clearance and targeting commercial supply and EBITDA break-even in FY27. Varenyam Healthcare's revenue grew to ₹58.4 Cr. The group's FY26 capital expenditure was ₹35.67 Cr, underpinning future growth in regulated markets.